Abstracts tagged "Adalimumab and psoriatic arthritis"

Abstract Number: 2970 • 2017 ACR/ARHP Annual Meeting
Inhibition of Radiographic Progression in Psoriatic Arthritis By Adalimumab Independent of the Control of Clinical Disease Activity
Robert B.M. Landewé¹, Christopher T. Ritchlin², Laura C Coates³, Daniel Aletaha⁴, Benoît Guérette⁵, Ying Zhang⁵, Fabiana Ganz⁶ and Maja Hojnik⁷, ¹University of Amsterdam, Amsterdam, Netherlands, ²Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ³University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie AG, Baar, Switzerland, ⁷AbbVie, Ljubljana, Slovenia
Background/Purpose : Patients (pts) with psoriatic arthritis (PsA) may experience structural damage and irreversible functional impairment if not treated appropriately. Treatment with TNF inhibitors in…
Abstract Number: 2894 • 2015 ACR/ARHP Annual Meeting
The Majority of Patients with Moderate to Severe Psoriatic Arthritis Had Existing Structural Damage, Predisposing Them to Further Progression, Which Was Markedly Inhibited By Adalimumab
Pranav Sheth¹, Philip J. Mease², Yihan Li³, Fabiana Ganz⁴ and Maja Hojnik⁵, ¹Group Health Associates, Trihealth, Cincinnati, OH, ²Seattle Rheumatology Associates, Seattle, WA, ³AbbVie Inc., North Chicago, IL, ⁴Neuhofstrasse 23, AbbVie AG, Baar, Switzerland, ⁵AbbVie, Ljubljana, Slovenia
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) may experience structural damage if not appropriately treated. The purpose was to determine 1) the frequency of radiographic…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.